Vast parts of mammalian genomes encode for transcripts that are not further translated into proteins. The purpose of the majority of such noncoding ribonucleic acids (RNAs) remained paradoxical for a long time. However, a growing body of evidence demonstrates that long noncoding RNAs are dynamically expressed in different cell types, diseases, or developmental stages to execute a wide variety of regulatory roles at virtually every step of gene expression and translation. Indeed, long noncoding RNAs influence gene expression via epigenetic modulations, through regulating alternative splicing, or by acting as molecular sponges. The abundance of long noncoding RNAs in the cardiovascular system indicates that they may be part of a complex regulatory network governing physiology and pathology of the heart. In this review, we discuss the multifaceted functions of long noncoding RNAs and highlight the current literature with an emphasis on cardiac development and disease. Furthermore, as the enormous spectrum of long noncoding RNAs potentially opens up new avenues for diagnosis and prevention of heart failure, we ultimately evaluate the futuristic prospects of long noncoding RNAs as biomarkers, and therapeutic targets for the treatment of cardiovascular disorders, as well.
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lncRNAs in a partly tissue-and cell-type-specific manner, suggesting their functional relevance. However, because of their recent discovery, low degree of conservation across species, and current methodological limitations for their study, relatively few lncRNAs have been functionally characterized to date. 4 In this review, we give an overview of the manifold mode of action of lncRNAs and highlight the current literature on lncRNAs at the origin of cardiovascular development and disease. We further discuss the clinical potential of lncRNAs for the development of novel diagnostic and therapeutic strategies.
ThE ADvENT of lncRNAs: MoDEs of ACTIoN
Despite a few long-known, functionally characterized lncRNAs (eg, X-inactive specific transcript [XIST] 5 or telomerase RNA component [TERC] ), 6 the full spectrum at which lncRNAs regulate phenotype and disease is only beginning to be understood. The development of new technologies for transcriptome-wide massive parallel sequencing led to the discovery that vast parts of mammalian genomes are actively transcribed into RNA, but only a minor fraction, equivalent to 2% to 3% of the genome, is further translated into protein. 7, 8 The majority represents a heterogeneous group of noncoding RNAs comprising ribosomal RNA, transfer RNA, lncRNA, microRNA (miRNA), circular RNA, and other small RNA molecules (Figure 1 ). lncRNAs are historically defined by their size as RNA molecules >200 nucleotides. Because this description inadequately describes the plethora of lncRNAs discovered to date, they are now subclassified by their gene location into sense, sense intronic, antisense, bidirectional, or intergenic lncRNAs ( Figure 2 ). However, there are no hard and fast rules about the classification of lncRNAs yet, and, because of their extremely versatile nature, it seems unlikely that strict rules can be defined. For example, the antisense lncRNA depicted in Figure 2 shows a natural antisense transcript that fully overlaps with a protein-coding gene on the opposite strand, but antisense lncRNA may only partially overlap, and the sense transcript can also be another noncoding transcript. 9 If the cellular function of certain lncRNAs is known, they are more accurately divided into functional categories as signal, decoy, guide, enhancer, scaffold, molecular sponge, or circular lncRNAs. 2 lncRNAs are transcribed by RNA polymerase II or III, 7,10 may be multiexonic, 5′-capped, and polyadenylated. 11 lncRNAs are localized in the nucleus or the cytoplasm where they may regulate gene expression at transcriptional or posttranscriptional levels, respectively. The latter can occur by lncRNAs acting as molecular sponges that compete with mRNAs for the binding of miRNAs and thus dampen the mRNA-destabilizing potential of miRNAs. One example of such a competing endogenous RNA (ceRNA) is the cardiac hypertrophy-related factor Chrf, a lncRNA that sponges miR-489 and is implicated in the cardiomyo-cyte hypertrophic response in an angiotensin II mouse model. 12 Moreover, lncRNAs may also interfere with protein translation by blocking, stabilizing, or destabilizing mRNAs. 13 By contrast, nuclear localized lncRNA (>80% of known lncRNAs 14 ) predominantly function as modulators of gene expression at the epigenetic and transcriptional level in cis or trans, which refers to the relative lncRNA gene location, in close proximity or distant to their target genes, respectively.
Signal lncRNAs are those that are expressed at only a specific time and place to process various stimuli. 15 At such a specific time, the expressed lncRNA may interact with chromatin-modifying enzymes (eg, histone methyltransferases) and, in turn, silence target genes through transcriptional blockade or heterochromatin formation. For example, lncRNA KQT member 1 opposite strand/ antisense transcript 1 (KCNQ1OT1) associates with the histone methyltransferases G9a and polycomb repressive complex 2 (PRC2) to form a repression domain in cis but also to silence genes in trans. 16 Decoy lncRNAs repress transcription in an indirect way by binding regulatory factors such as transcription factors, chromatin remodelers, or other RNA-binding proteins, thus sequestering them from their specific target sites. By this definition, ceRNAs may also be considered decoys specific for miRNAs. The telomeric repeat-containing RNA (TERRA) is an example of a decoy lncRNA that is implicated in the regulation and protection of telomeres. 17, 18 TERRA physically associates with telomerase reverse transcriptase, the catalytic subunit of the telomerase complex that adds telomeric repeat sequences onto telomeres to protect chromosome ends from fraying. 19 Telomeric heterochromatin-bound TERRA has been suggested to bind and sequester telomerase, thus keeping telomerase close to the chromosome ends but blocking its action. 20 Interestingly, TERRA appears to be cell cycle regulated and is inversely correlated to the activity of telomerase, ie, telomeres are elongated during S phase when TERRA levels are lowest. 21 Because short telomeres in peripheral blood represent cardiovascular risk factors and are associated with atherosclerosis, heart failure, and hypertension, 22 it will be of interest if such a link also exists between TERRA and cardiovascular disease.
Guide lncRNAs bind regulatory proteins (transcription factors, chromatin remodelers) to tether them as a ribonucleoprotein complex to their target sites. Guide lncRNA can act in cis or trans and can mediate gene activation or repression depending on whether the guided complexes are transcription factors, activating histone methyltransferases such as the MLL complex, or repressive complexes (eg, PRC2). 15 Enhancers are regulatory genomic elements that are located far away from the promoter or transcriptional start site of their target genes. 23 Enhancer lncRNAs are cis-acting molecules that are generated from active enhancer elements and are required for the enhancer function and subsequent activation of gene expression of neighboring protein-coding genes. [24] [25] [26] For example, Ørom and colleagues 26 demonstrated that knockdown of the human enhancer lncRNA ncRNA-a7 leads to decreased mRNA levels of the adjacent transcriptional repressor SNAIL1. Among the 5 genes in this locus, the knockdown of ncRNA-a7 selectively affects SNAIL. Mechanistically, enhancer lncRNAs may function by promoting chromosomal looping, thus establishing or maintaining the interaction of enhancer and promoter elements. 27 Nuclear-localized lncRNA molecules also play a critical role in coordinating mRNA splicing, which may aid in achieving protein diversity. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a well-conserved lncRNA with abundant expression in the heart, has been established as a master regulator for splicing of NDRG2 and EIF4H mRNA, 28 presumably via interaction with splicing factor ASF/SF2. 29 Moreover, the evolutionary conserved antisense lncRNA asFGFR2 influences the splicing of FGFR2 mRNA specifically in mesenchymal cells via recruitment of PRC2 and KDM2a (a H3K36 demethylase), thus creating a splicing-specific chromatin signature. 30 lncRNAs can also serve as molecular scaffolds that not only aid in the assembly of multimeric ribonucleoprotein complexes, but also may be functional components of the same. A prime example of a scaffold lncRNA is the telomerase RNA component TERC. The functional telomerase holoenzyme relies on the defined assembly of the 2 core components telomerase reverse transcriptase and TERC, and accessory proteins (DKC1, NOP10, figure 1. Transmission of genetic information.
Primary transcripts give rise to proteincoding messenger RNAs (mRNAs) and a large variety of noncoding RNAs. mRNAs are further translated into protein. However, the majority of noncoding RNA molecules can be broadly subdivided into long noncoding RNA (lncRNA), circular RNA (circRNA), microRNA (miRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), etc, which act in the nucleus or cytoplasm. figure 2. lncRNA classification in the context of different genomic locations.
On the basis of genomic location and orientation to protein-coding genes (PCGs), there are 5 major classes of lncRNAs. Sense lncRNAs span multiple intron or exons within a PCG. Intronic lncRNAs are located within one of the introns of coding gene on the sense strand. Antisense lncRNAs are transcribed from the opposite strand of a PCG. Bidirectional lncRNAs are situated on the opposite strand but within 1 kb of the promoter on the sense strand. They are transcribed in the direction opposite to that of the promoter on the sense strand. Intergenic lncRNAs are transcripts located between 2 PCGs. lncRNA indicates long noncoding RNA. 
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NHP2, and GAR1), as well. 31 Strikingly, in addition to the important roles for telomerase assembly and complex stability, TERC also acts as the RNA template for the RNA-dependent DNA polymerase activity of telomerase reverse transcriptase to add TTAGGG telomeric repeats onto telomeres. 32 In complex with proteins, lncRNAs may also mediate protein trafficking or signaling. For instance, ncRNA repressor of nuclear factor of activated T cells (NFAT) (Nron) regulates nuclear trafficking of NFAT presumably through controlling de/phosphorylation of NFAT and the interaction with nuclear import factors. 33, 34 Similarly, the human dendritic cell-specific lncRNA lnc-DC directly binds the transcription factor STAT3 in the cytoplasm. This interaction blocks binding of the phosphatase SHP1, thus promoting the phosphorylated, active form of STAT3. 35 lncRNAs also fulfill essential roles during X-chromosome inactivation and gene-specific silencing. lncRNA XIST is the master regulator of X-chromosome inactivation in female cells to ensure dosage compensation for a balanced X-specific gene expression between male and female cells. Interestingly, XIST itself is exclusively transcribed from the silenced X chromosome and, thus, is a cis-acting lncRNA. 36, 37 Several other lncRNAs involved in allele-specific gene silencing, known as genetic imprinting, have been described, eg, KCNQ1OT1 38 and H19. 39 Importantly, a precisely balanced expression of these imprinted loci is critical for development and disease, including the heart, because dysregulated KCNQ1OT1 and H19 contribute to congenital long-QT syndrome and cardiomyocyte hypertrophy, respectively. 38, 40, 41 Circular RNAs (circRNAs) belong to novel category of lncRNAs. They are generated from intronic and/or exonic sequences through backsplicing of the 5′ and 3′ ends of a given transcript, thus forming a loop without 5′ → 3′ polarity or polyadenylated tail. This makes them resistant toward digestion by exonucleases, and, hence, cir-cRNAs are more stable than linear RNAs. The existence of circRNAs has been known for decades, but, because of their small number and low abundance, they were considered as splice artifacts. However, next-generation sequencing technology and bioinformatics have revealed that there may be thousands of circRNAs present in human cells. 42 In marked contrast to lncRNAs, most circRNAs are conserved across species presumably because of their overlap with protein-coding sequences. 43 The expression of circRNAs seems to be regulated in tissue and developmental stage-specific manner suggest- Nuclear-localized lncRNA regulate gene expression in various modes such as in a response to stimuli (signal), sequester transcription factors/protein complex (decoy), bring together multiprotein complexes (scaffold) or guide transcription factors/protein complex to specific target site (guide) to activate or repress transcription and induce chromosomal looping to increase association between enhancer and promoter region (enhancer). Cytoplasmic lncRNAs (linear or circular) can stabilize ribonucleoprotein complexes, regulate mRNA stability or sponge miRNAs, thus controlling translational events. Further regulatory functions may involve protein signaling (eg, phosphorylation status) and trafficking. lncRNA indicates long noncoding RNA; and miRNA, microRNA.
ing their functional relevance. 44 Indeed, recent research implies circRNAs act as miRNA sponges, 45 and splice and transcriptional regulators of the parental gene, as well. Furthermore, evidence is emerging that circRNAs may play key roles in disease processes (recently reviewed in references 42, 46 ). Because many circRNAs can be detected extracellularly in bodily fluids in a relatively stable manner, they might hold great potential to serve as biomarkers of disease 47 (Figure 3 ).
lncRNAs IN CARDIovAsCuLAR DEvELoPMENT
In addition to a handful of prototypic examples for ln-cRNAs with specific roles during development, such as XIST or TERC, the vast expression of lncRNA (tissue-specific or stage-specific expression during development) suggests that they may also be critically involved in the orchestration of cardiac developmental processes. Indeed, recent studies dedicated to cataloging lncRNAs revealed their widespread dynamic expression during cardiovascular lineage commitment and heart development, as well. In this context, Klattenhoff and colleagues reasoned that lncRNAs expressed in embryonic stem cells (ESCs), which, in the course of differentiation, become restricted to a certain cell type, may be essential for lineage commitment. Their detailed comparative expression analysis identified cardiac-specific lncRNA Braveheart (Bvht). 48 Bvht is not required for ESC self-renewal but is indispensable for proper ESC cardiovascular lineage commitment and differentiation into cardiomyocytes in vitro. Mechanistically, Bvht was suggested to regulate the activation of mesoderm posterior 1 (Mesp1), a master regulator of downstream key transcription factors of cardiac development (eg, NKX2.5, GATA4, GATA6, HAND1, HAND2, and TBX20). Bvht acts in trans as a decoy lncRNA and physically associates with SUZ12, a core component of PRC2. Through this interaction, Bhvt titrates away the SUZ12/PRC2 complex from its target sites and thus inhibits trimethylation of histone lysine H3K27 and the formation of repressive chromatin marks ( Figure 4A ). Moreover, Bvht depletion in isolated neonatal mouse cardiomyocytes was shown to impair the maintenance of the cardiac cell fate. 48 However, whether Bvht is similarly required for cardiac specification in the developing organism remains to be demonstrated. In contrast, murine lncRNA Fendrr is transiently expressed in nascent mesoderm and was shown to be a crucial regulator of heart and body wall development. Accordingly, lack of Fendrr led to embryonic lethality around E13.75 in this study. 49 A subsequent study showed that, apart from heart, deletion of Fendrr also results in additional defects in lung and gastrointestinal tract. Despite the seemingly more severe defects, embryonic lethality was not observed; instead, homo-zygous mutant pups died perinatally despite the similar genetic background. 50 The fact that both studies used different strategies to delete Fendrr (replacement of the first exon by a transcriptional stop sequence 49 versus replacement of the lncRNA gene by a lacZ cassette 50 ) is a rather unsatisfactory explanation and further studies are needed to elucidate the observed discrepancies. Mechanistically, Fendrr also interacts with the PRC2 histone methyltransferase complex. In contrast to the decoy function of Bvht, Fendrr can bind the promoters of the transcription factors Foxf1 and Pitx2 (critical for early cell fate decision) and, therefore, acts as guide ln-cRNA that anchors PRC2 to its target sites. 49 Strikingly, Fendrr also interacts with the histone methyltransferase complex trithorax/mixed lineage leukemia (TrxG/MLL), 49 which catalyzes trimethylation of H3K4, 51 an activating chromatin mark. It has been speculated, that the dual function of Fendrr may be required to equilibrate H3K4 and H3K27 methylation to orchestrate gene programs during mesoderm differentiation. 52 Ounzain et al 53 performed ultradeep sequencing and analyzed the differentiation-associated transcriptome by comparing murine ESCs with cells at the cardiac precursor stage. Over 4000 multiexonic, polyadenylated lncRNAs, 2608 of which were not annotated before were identified. More than 1000 of those novel lncRNAs were either up-or downregulated during differentiation. Interestingly, by integrating ChiP-Seq data, 630 novel lncRNAs (57%) were identified as enhancer lncRNA on the basis of their overlap with active enhancer elements defined by the presence of H3K4 monomethylation and H3K27 acetylation chromatin signatures (in contrast to promoter-associated lncRNAs characterized by H3K4 trimethylation). Hence, this study supports the previous evidence for enhancer-associated regulatory ln-cRNAs essential for enhancer function. [24] [25] [26] Moreover, it extends the current knowledge by demonstrating that enhancer lncRNAs are dynamically expressed from enhancers proximal to genes encoding cardiac regulatory proteins that are essential during cardiac lineage specification, and during cardiac pathophysiological processes, as well. 53 Along those lines, Carmen (cardiac mesoderm enhancer-associated noncoding RNA) is a novel, evolutionarily conserved enhancer-associated lncRNA that governs cardiac lineage specification and maintenance. 54 Interestingly, in mice Carmen is located on the opposite strand directly adjacent to Bvht (note, there is no human orthologue of Bvht) which is similarly involved in cardiogenesis. 48 Experimental silencing of Carmen simultaneously blocks the expression of Bvht suggesting that Carmen acts upstream to control Bvht and cardiac specification. 54 In contrast, the expression of 2 developmentally important miRNAs, miR-143 and mir-154, 55, 56 which are transcribed from the same locus as Carmen, seem to be expressed as independent transcripts (ie, Carmen is not a host gene of miR-143 or 
STATE OF THE ART
miR154) because their expression is not decreased on Carmen depletion. 54 The evident contribution of lncRNA to various developmental processes is achieved in part through dynamic, stage-specific expression of certain lncRNAs. This therefore implies that lncRNA expression patterns in developing organisms/organs may differ significantly from those in adults under homeostatic conditions. In this regard, a recent work systematically characterized ln-cRNAs in human fetal and adult heart. 57 Based on UCSC genome browser and NCBI Refseq annotation a catalog of ≈12 000 lncRNA was investigated. RNA sequencing revealed that ≈5000 lncRNAs are expressed in both fetal and adult heart tissue, whereas 277 lncRNAs were differentially regulated (164 up and 113 down in fetal versus adult). Correlation of differentially expressed ln-cRNAs with specific chromatin states (ie, H3K4 mono-or trimethylation) suggests that the expression differences in fetal and adult heart, at least in part, underlie epigen-etic regulation. Analysis of structural lncRNA features showed a bias toward shorter transcripts (<1 kb) in fetal heart and a higher percentage of sense lncRNA in adult heart (18% versus 7%). 57 Werber et al 58 and Matkovich et al 59 performed comprehensive transcriptome analyses of the embryonic heart at E8.25 and E14, respectively. Both studies identified a large number of tissue-and developmental stage-specific lncRNA, but no individual lncRNA has been functionally characterized. Whether these global changes in lncRNA expression are functionally linked to cardiogenesis remains unknown. Nevertheless, because the sequencing data are publicly accessible through data repositories, they provide a valuable data resource for the analysis of individual lncRNAs. This similarly applies to other studies reporting large sequencing data sets, hence, promoting transparency, and allowing comparative analyses in a rapidly evolving research area in the field of lncRNA biology, as well. Kurian et al 60 also used RNA deep sequencing to screen for novel human lncRNAs underlying vertebrate cardiovascular development. This study particularly focused on lncRNAs during the differentiation of human ESCs into terminally differentiated vascular endothelial cells. 61 Several hundred lncRNAs were found to be expressed in a developmental stage-specific manner (ie, in mesoderm committed cells, early cardiovascular progenitor cells, committed vascular progenitor cells, and vascular endothelial cells). After a 5-step filtering process, the authors selected 3 lncRNA candidates for further characterization, which are specifically expressed in pluripotent stem cells, vascular progenitors, or mature endothelial cells, and named them TERMINATOR, ALIEN, and PUNISHER, respectively. Inhibition of these lncRNAs in zebrafish and different murine and human cell models revealed critical roles of TERMINATOR for pluripotent stem cell identity, ALIEN for cardiovascular development, and PUNISHER for the maintenance of endothelial cell function. 60 In line with lncRNAs being important for endothelial cell commitment and function, overexpression of human vascular-enriched lncRNA SENCR (smooth muscle and endothelial cell-enriched migration/differentiation-associated lncRNA 62 ) leads to enhanced early mesodermal and endothelial commitment during in vitro differentiation, and to an increased angiogenic potential in human umbilical endothelial cell, as well. 63 In contrast, SENCR was found downregulated in endothelial cells (isolates from superficial forearm veins) from patients with premature coronary artery disease 63 and knockout of SENCR inhibits smooth muscle cell migration. In contrast to the majority of lncRNAs SENCR, is localized in the cytoplasm, 62 which highlights that similar cellular processes (ie, lineage commitment or differentiation) are fine-tuned by different lncRNAs at multiple levels.
lncRNAs IN CoNgENITAL hEART DIsEAsE
In newborn humans, congenital heart disease (CHD) is the most frequent congenital malady with a prevalence of up to 1.3% live births. 64, 65 The broad involvement of lncRNAs in cardiac developmental processes makes a link between lncRNAs and CHD likely. However, no individual human lncRNA has been causally associated with CHD to date. Nevertheless, a recent study compared the expression profiles of cardiac tissue from fetuses with ventricular septal defect, one of the most common CHDs, and normal hearts. Expectedly, >1500 lncRNAs were differentially expressed (880 upregulated and 628 downregulated) in hearts with ventricular septal defect at the gestational age between 17 and 20 weeks (in comparison with age-matched cardiac tissue from voluntarily aborted fetuses). Several rounds of bioinformatics filtering then identified conserved and cardiac specific ln-cRNAs ENST00000513542 and RP11-473L15.2 to be associated with ventricular septal defect. 66 Interestingly, gene ontology analysis of protein-coding genes adjacent to the differentially expressed lncRNAs identified biological pathways implicated in cell differentiation, cell fate commitment, and heart growth, which is in line with the importance of cis-acting lncRNAs in cardiac developmental processes as discussed above.
The therapeutic value of lncRNA in the context of CHD is yet unexplored and the development is difficult to predict at present. However, cell-free lncRNAs (present in the mother's blood and potentially amniotic fluid) may become important biomarkers for the detection, and the stratification of different forms of CHD, as well (see Circulating Noncoding RNAs as Biomarkers of Disease).
lncRNAs IN CARDIovAsCuLAR DIsEAsE
In addition to cardiac development, advanced highthroughput sequencing techniques also unveiled the expression of thousands of lncRNAs expressed in mature, adult cells. Many of these transcripts undergo specific expression changes in response to pathological heart conditions and experimentally induced cardiac stress in humans and rodent models, respectively. Consequently, lncRNA may reflect key regulators of homeostasis, and disease processes, as well, in the developed heart and, thus, may serve as biomarkers or as therapeutic targets for the treatment of cardiac disease in the future. Although this area of research is still in its infancy, pharmacological manipulation of several lncRNAs in the mouse heart after, eg, myocardial infarction or pressure overload-induced hypertrophy, have demonstrated promising results and proof-of-concept for the therapeutic potential of lncRNAs.
In a pioneer study, Han and colleagues identified a heart-specific cluster of cardioprotective antisense ln-cRNAs in the murine myosin heavy chain 7 (Myh7) locus, which was termed myosin heavy chain-associated RNA transcripts, or Mhrt. 67 Mhrt is downregulated in pressure overload induced hypertrophy after transaortic constriction, and the rescue of Mhrt by transgenic overexpression protects mice from pathological hypertrophy and heart failure. The nuclear-localized Mhrt binds the chromatin-remodeling factor BRG1 (a component of the BRG1-HDAC-PARP chromatin repressor complex) under homeostatic conditions and occupies its helicase domain, which is essential for chromatin binding of BRG1. Thus, Mhrt acts as decoy lncRNA to prevent BRG1 binding and epigenetic repression of its targets. Cardiac stress increases BRG1 levels leading to disequilibrium between Mhrt and BRG1. Consequently, free BRG1 can now repress its target gene Myh6 (and Mhrt) that promotes the pathological isoform switch from Myh6 to Myh7, a hallmark of developing heart failure 68 (Figure 4B) . Importantly, the human Myh7 locus also gives rise to an antisense transcript that is analogous to Mhrt in primary and secondary structure. Human MHRT is 
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repressed in tissue samples from patients with hypertrophic, ischemic or idiopathic cardiomyopathy. Thus, epigenetic regulation by Mhrt seems to be a conserved mechanism. 67 In addition to cardioprotective Mhrt, Viereck and colleagues 69 recently discovered a prohypertrophic lncRNA named cardiac hypertrophy-associated transcript, Chast. Chast is transcriptional target of the NFAT and is upregulated in response to hypertrophic stimuli specifically in cardiomyocytes. Overexpression of Chast is sufficient to induce cardiomyocyte hypertrophy in vitro and in vivo, whereas pharmacological inhibition ameliorates cardiac remodeling and hypertrophy in a transaortic constriction mouse model. This study provides the first proof-of-principle lncRNA-targeting therapy for the treatment of cardiac hypertrophy, importantly, in the absence of early signs on toxicological side effects. Chast has a human homologue, the expression of which is elevated in human ESC-derived cardiomyocytes on exposure to hypertrophic stimuli and also in hearts of patients with aortic stenosis in comparison with healthy hearts, thus suggesting that Chast is of translational relevance for humans. 69 Mechanistically, Chast was suggested to act in cis to control the expression of Plekhm1, a regulator of autophagy 70 that is located opposite to Chast. However, the precise role of the Chast/Plekhm1 interaction, likely to involve epigenetic regulation, remains to be demonstrated. Similar to Chast, Wang et al recently identified lncRNA Chaer, or cardiac-hypertrophy-associated epigenetic regulator, another lncRNA required for the development of cardiac hypertrophy. 70a Chaer directly interacts with PRC2 and thereby inhibits the formation of transcriptionally silent chromatin at prohypertrophic loci.
In 2 separate studies, the global lncRNA expression dynamics in human endothelial cells after exposure to hypoxic conditions have been catalogued. 71, 72 Fiedler et al 71 identified hypoxia-sensitive lncRNAs LINC00323 and MIR503HG as crucial factors for endothelial cell biology in vitro, and ex vivo, as well, in human induced pluripotent stem cell-derived engineered heart tissues as a 3-dimensional model. Cytoplasmic LINC00323 serves as a scaffold for eIF4a3, thus controlling GATA2 translation, whereas nuclear-enriched MIR503HG acts in cis to control the expression of the adjacent miR-424 gene. Michalik et al 72 identified and functionally characterized lncRNA MALAT1 in endothelial cells whose expression is increased on hypoxia. MALAT1 inhibition in vitro and in vivo leads to impaired endothelial cell proliferation. Of note, MALAT1 associates with the PRC2 complex and therefore was suggested to modulate cellular proliferation by epigenetic modulation. 73 In addition, a recent publication assigned immune-regulatory functions to MALAT1. Interestingly, these functions do not reside in the primary transcript, but in a posttranscriptionally processed form named MALAT1-associated small cytoplas-mic RNA (mascRNA), which was demonstrated to play a role in cardiovascular innate immunity. 74 The lncRNAs Chrf, cardiac apoptosis-related lncRNA (Carl), and autophagy promoting factor (Apf) are 3 different ceRNA linked to cardiac pathologies. As mentioned above, Chrf serves as a sponge for miR-489. The target of miR-489 is the mRNA of the prohypertrophic factor myeloid differentiation primary response gene 88 (MYD88). 12 Carl sequesters miR-539, which, in turn, leads to derepression of PHB2 in cardiomyocytes. PHB2 is protein that maintains mitochondrial homeostasis and protects from mitochondrial fission and apoptosis. On pathological insults such as anoxia, Carl levels decrease, thus liberating miR-539 for PHB2 mRNA targeting. In vitro overexpression of Carl reduces mitochondrial fission and apoptosis induced by anoxia. 75 Because mitochondrial dysfunction is a hallmark of heart failure, 76 further in vivo studies are warranted to address the therapeutic potential of Carl for the treatment of heart disease. lncRNA Apf regulates autophagic cell death. Under pathological conditions, Apf is upregulated and sequesters miR-188-3p. This derepresses autophagypromoting gene ATG7, which, in turn, leads to deregulated autophagy and cell death. Accordingly, knock-down of Apf or overexpression of miR-188-3p reduces cell death in vitro, and in an ischemia/reperfusion mouse model, as well. 77 Along these lines, heart-related circRNA (Hrcr) was recently identified as the first competing endogenous cir-cRNA implicated in the protection from cardiac hypertrophy via targeting prohypertrophic miRNA, miR-223. Hrcr downregulation is provoked by hypertrophic stimuli such as transaortic constriction or isoproterenol treatment. In vivo delivery of Hrcr to overcome endogenous downregulation mitigates hypertrophic responses, including decreased cardiomyocyte size, decreased heart weight to body weight ratio, and improved cardiac function, as well, in comparison with a noncircular Hrcr control. 78 In contrast to Hrcr, no evidence for a miRNA sponge function of human circRNA cZNF292 could be found. cZNF292 is hypoxia regulated and exerts proangiogenic properties in human umbilical venous endothelial cells culture. 79 CircRNA circ-Foxo3 is associated with cell cycle progression in vitro in primary mouse cardiac fibroblasts. Silencing of circ-Foxo3 promotes cell proliferation, whereas overexpression results in cell cycle blockade through formation of an inhibitory complex with the cell cycle proteins CDK2 and p21. 80 Further evidence for a critical role of lncRNA, especially in human cardiac disease, stems from genomewide association studies. Myocardial infarction-associated transcript MIAT is a lncRNA that was identified in a large-scale case-control association study. 81 Comparison of 3435 individuals with myocardial infarction versus 3774 controls revealed 6 single-nucleotide polymorphisms in the MIAT locus that are significantly linked to a higher risk of myocardial infarction. One particular single-nucleotide polymorphism in exon 5 was shown to increase MIAT transcription in vitro. 81 Interestingly, MIAT levels measured in peripheral blood cells distinguish between patients with ST-segment-elevation (lower MIAT) and patients with non-ST-segment-elevation myocardial infarction. 82 lncRNAs ANRIL (antisense noncoding RNA in the INK4 locus), KCNQ1OT1, and MALAT1 also showed this association in the same study. 82 Although, the expression patterns of these lncRNAs in peripheral blood cells are altered in response to myocardial infarction, their usefulness as predictors of cardiac dysfunction was questioned because they have been measured in noncardiac tissues and, thus, lack cardiac specificity. 83 Functionally, MIAT may play a role in pathological angiogenesis by acting as ceRNA that targets miR-150-5p and vascular endothelial growth factor. 84 Another study suggests an interaction of MIAT with polycomb genes. 85 In another genome-wide association study comprising more than 23 000 individuals, a 58-kb region on chromosome 9p21 was identified that was consistently associated with coronary heart disease. Interestingly, the mechanism by which this susceptibility locus influences coronary heart disease risk caused speculations about unknown regulatory elements, because the 58-kb region is devoid of any protein-coding or miRNA genes. 86 However, it then became evident that this locus harbors lncRNA ANRIL 87 whose expression is associated with atherosclerosis risk 88 and vascular disease, in general. 89 Strikingly, ANRIL is expressed in multiple linear and circular isoforms. The expression of both forms correlates with the expression of the adjacent INK4/ARF tumor suppressor locus and the associated atherosclerosis risk. 90 On the molecular level, ANRIL exerts its function through association with epigenetic regulators PRC1 and PRC2 to silence the INK4b-ARF-INK4a tumor suppressor locus. 91 ANRIL transcripts contain an Alu sequence motif that is mirrored in the promoter sequences of ANRIL target genes. Through the interaction of the Alu motifs of the RNA and the chromatin, ANRIL tethers PRCs to specifically silence gene expression. 92 Of note, similar to ANRIL, numerous genome-wide association studies uncovered disease-associated genomic loci or single-nucleotide polymorphisms that are located in such gene deserts. Because of the widespread distribution of lncRNAs throughout the genome, it is likely that their association with disease (susceptibility) is currently strongly underestimated. If undiscovered lncRNA genes indeed reside in many of these loci, the corresponding transcripts may hold the potential to serve as biomarkers of associated diseases.
As it is the case for developmental processes, several studies have been dedicated to the identification of cardiac pathology-specific lncRNAs by using comparative microarray or deep sequencing approaches. For example, Zangrando et al 93 used microarray analysis to study lncRNAs that were deregulated 24 hours after myocardial infarction in mice. Thirty lncRNAs were either up-or downregulated. Time-course analysis of the 2 most strongly upregulated lncRNAs (myocardial infarction-associated transcript 1 [Mirt1] and 2 [Mirt2]) revealed that their expression peaked 24 hours after myocardial infarction and returned to baseline 2 days later. Although no functional data were provided, this study again demonstrates that lncRNAs are dynamically expressed during disease processes and that the changes in expression can occur rapidly. Another study identified a large number of novel (1521 unannotated versus 988 UCSC-annotated) and partially deregulated lncRNAs through RNA deep sequencing from tissue of the infarct border zone 4 weeks after myocardial infarction (versus sham operated) in mice. 94 Interestingly, 38% of the novel lncRNAs are heart specific, which rises to 60% when only the set of deregulated transcripts are considered. The majority of those are associated with active, cardiac-specific enhancer. Importantly, syntenic BLASTZ alignments revealed that 73% of the newly identified lncRNAs map to the human genome, ie, have predicted human orthologues, few of which were confirmed by quantitative reverse transcriptase polymerase chain reaction in human heart tissue. For instance, lncRNA candidate Novlnc6, a potential regulator of Nkx2. 5 and Bmp10, has a human orthologue that, along with Nkx2.5, is deregulated in patients with dilated cardiomyopathy but not with aortic stenosis. 94 Nevertheless, the observed level of conservation is surpris- 
ing given that one of the main characteristics of lncRNAs is defined by their overall low degree of conservation, even between closely related species. However, this finding is likewise intriguing because it offers the possibility to study human lncRNAs critically involved in cardiac disease in a rather focused way.
In summary, several human and murine lncRNAs associated with cardiac development and disease have been identified and partially characterized to date ( Figure 5 ). Given the large number of lncRNAs in mammals and the rapidly evolving research field, the list of lncRNAs implicated in these processes is expected to grow exponentially in the future, and, thus, this will potentially contribute to improving the armamentarium in cardiovascular prevention and intervention.
CIRCuLATINg NoNCoDINg RNAs As BIoMARkERs of DIsEAsE
Various RNA species can be found as cell-free RNA in the circulation. In particular, the levels of a number of circulating miRNAs have been reported to change in response to myocardial infarction, coronary artery disease, and heart failure and therefore are proposed to be putative biomarkers of cardiac disease [95] [96] [97] [98] (miRNA as biomarkers have been reviewed in detail elsewhere, eg, reference 98 ).
In contrast to miRNAs, the identification of lncRNA as biomarkers of disease is still at an early stage. A prominent example is the lncRNA LIPCAR (long intergenic noncoding RNA predicting cardiac remodeling) that is differentially abundant in plasma from patients with or without severe left ventricular remodeling after myocardial infarction. Interestingly, LIPCAR is expressed from the mitochondrial genome, highlighting that lncRNAs can also originate from extranuclear DNA. LIPCAR not only acts as a marker of cardiac remodeling, but LIPCAR levels are also associated with a higher risk of mortality in patients with heart failure. 99 More recently, lncRNA urothelial carcinoma-associated 1 (UCA1) was proposed as a novel biomarker of acute myocardial infarction. UCA1 plasma levels are significantly lower 12 hours post-myocardial infarction but elevated after 72 figure 6. Noncoding RNAs as biomarkers of cardiovascular disease. hours, in comparison with healthy controls. 100 However, the usefulness of UCA1 as a biomarker for acute myocardial infarction is probably limited because its predictive power is inferior to classical markers such as cardiac troponin I or creatine kinase. 100 Nevertheless, UCA1 is an additional example that highlights the feasibility of developing lncRNA diagnostics of high clinical relevance. UCA1 has been identified in urine as a noninvasive biomarker for early diagnosis of primary bladder cancer. 101 This discovery has then led to the development of an assay for direct detection of UCA1 in urine samples. This relatively effortless assay is able to detect bladder cancer at high sensitivity and specificity and at moderate costs (estimated at $8 per test). 102 A recent study investigated the lncRNA content in the plasma of 62 pregnant women with fetal CHD in comparison with 62 age-matched healthy controls. With the use of microarray analysis, thousands of lncRNAs were found aberrantly expressed. Confirmation by quantitative polymerase chain reaction and receiver operating characteristic curve analysis identified 5 of the most differentially expressed lncRNAs (LINC00281, H19, LOC100507463, HOXD-AS1, ZNF192P1) to have a high predictive value for fetal CHD. Moreover, these 5 lncRNAs were found to be of potential use in discriminating different forms of CHD. Accordingly, LINC00281, ZN-F192P1, LOC100507463, and HOXD-AS1 were associated with ventricular septal defect; LOC100507463 and HOXD-AS1 were associated with atrial septal defects, and LINC00281, H19, LOC100507463, and HOXD-AS1 were associated with Tetralogy of Fallot 103 (Figure 6 ).
In further support of lncRNAs being valuable biomarkers, a study was performed to address the global changes of circulating (plasma) lncRNA in a mouse model of isoproterenol-induced acute heart failure. More than 1500 lncRNAs were found up-and downregulated during heart failure. Interestingly, the global expression changes in plasma are distinct from the dynamics in the heart, and many of the differentially expressed ln-cRNAs are inversely correlated in heart and plasma. 104 This suggests that circulating lncRNAs do not simply reflect spilled cellular content from dying cardiomyocytes. Indeed, both miRNAs and lncRNAs can be secreted by most cells inside of membrane microvesicles such as exosomes, which protects them from degradation by ribonucleases in the extracellular environment. miRNAs are further stabilized by cosecretion and binding to Argonaute 2 protein, the key effector of miRNA-mediated silencing. 105 Whether such a protective mechanism for lncRNA exists is presently unknown. This raises the question of whether lncRNAs are better biomarkers than protein-coding mRNAs, which are generally expressed at higher levels and are also present in exosomes. However, the facts that lncRNAs show greater tissue specificity in comparison with mRNAs and that they can form very complex and stable secondary structures may give them an edge over mRNAs to serve as biomarkers. 106 Finally, circRNAs are also found in the extracellular fraction in the circulation, and in other bodily fluids, as well; because of their stability, they might be even better suited biomarkers of disease, but they are currently awaiting detailed characterization. 47 lncRNA-BAsED ThERAPEuTICs: fuTuRE oR fICTIoN?
As discussed above, a plethora of lncRNAs are dysregulated in heart pathologies. Several studies in mice have highlighted that manipulation of individual lncRNAs is sufficient to halt or ameliorate cardiac disease processes. This was achieved not only through transgenic gene activation (eg, Mhrt), but also via pharmacological inhibition of the lncRNA transcript (eg, Chast) where lncRNA candidates in heart pathologies were down-or upregulated, respectively. 67, 69 Especially the development of antisense chemistries designed for the degradation of RNA molecules, and the development of novel vectors for gene transfer, as well, have spurred interest in using figure 7. Noncoding RNA-based therapeutic approaches.
Noncoding RNA therapeutics (antisense chemistries or the noncoding sequence itself) may be delivered via viral particles, via nanoparticles, or through direct injection of the therapeutic molecule. Therapies are aimed at either inhibiting endogenous noncoding RNAs or designed to deliver the noncoding RNA (gene) for (re)activation. LNA indicates locked nucleic acids; lncRNA, long noncoding RNA; and miRNA, microRNA. lncRNAs as therapeutic targets for the treatment of cardiovascular disease. In this regard, strategies for the manipulation of miRNAs, which are also powerful regulators in cardiac disease programs, do certainly serve as a role model. In particular, antisense molecules for the inhibition of miRNAs that are specifically implicated in disease have already entered clinical trials. The most prominent example is Miravirsen, an antisense nucleotide drug for the treatment of patients with chronic hepatitis C virus infection. Miravirsen was designed to specifically inhibit miR-122 in the liver because this miRNA is indispensable for stability and propagation of the virus. 107, 108 Importantly, a multicenter phase 2a study of Miravirsen revealed a prolonged dose-dependent reduction of viral RNA in the absence of dose-limiting adverse events or the occurrence of viral resistance. After 5 weeks of treatment and a 14-week follow-up, the hepatitis C virus RNA was undetectable in 4 of 9 patients in the group with the highest Miravirsen dose. 109 However, antisense treatments in the heart deviate from this example because they do not inhibit virus-host interactions, but rather aim at keeping noncoding RNAs in check that have pathologically elevated levels.
On the molecular level, miRNAs are targeted through antisense oligonucleotides that are chemically modified for efficient cellular uptake. Antagomirs are perfect match antisense molecules, whereas anti-miRs are locked nucleic acids (LNAs) that have an 8-or 15-base antisense stretch with ribose 2′-fluoro-and 2′-O-methoxyethyl groups to provide high target affinity. 110 Following the latter principle, so called LNA-GapmeRs have been developed to specifically target lncRNAs. A GapmeR contains a free DNA stretch (which is the Gap) flanked by 14 to 16 LNA nucleotides required for target specificity. Once bound to a target lncRNA, the DNA gap elicits RNase H-mediated cleavage of the RNA. In addition to GapmeR inhibition, vector-based delivery of antisense molecules may represent another strategy for lncRNA downregulation. Similar gene therapy approaches may also be used for the delivery of lncRNA genes in those cases where the endogenous gene is downregulated in cardiac disease. Nanoparticles may also be of use for the delivery of both lncRNA genes and antisense molecules. Nanoparticles can potentially be tailored to achieve a cell type-specific delivery, and at the same time reduce side effects and stabilize the cargo (Figure 7) .
Studies in rodents have shown impressive results and provided proof of concept; likewise, the therapeutic use of lncRNA-based strategies looks promising. However, solutions to a few specific bottlenecks need to be found: many lncRNAs are poorly conserved in sequence across species, and thus the search for an appropriate preclinical model is a prerequisite. Second, intensive research needs to be done to understand the precise role of lncRNAs during homeostasis and disease processes. Third, to our knowledge, therapeutic lncRNA treatments are limited to rodent models; hence, a least a handful of crucial questions remain to be addressed before being translated to humans: Do GapmeR chemistries or vector-based approaches work in bigger animal models (eg, pigs, primates)? Does a given lncRNA function in the same way in humans and animals? How can they be delivered to specific sites (ie, organ, cell type)? Are they safe to use? What are potential side effects?
In conclusion, human lncRNA-based therapies begin to appear at the horizon. Given that lncRNAs are critically involved in disease processes, are potentially druggable, and are expressed in large numbers, further efforts to develop such lncRNA-based therapeutics look promising.
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